Avid Bioservices Inc (CDMO)

[Big On Tarvy]

Co-Infection Dosing Schedule

I would be interested to learn what others think about the medical / immuno-stimulatory implications of the new dosing regimen in the HCV/HIV co-infection study.

In the Ph Ib HCV multi-dosing study patients received 4 doses over 2 weeks. In the new co-infection study patients will receive 8 doses over 8 weeks.

As compared with the Ph Ib HCV study, it seems results in the co-infection study ought to be much better because therapy regimen is lasting four times longer (8 weeks rather than 2) and patients are receiving twice as much Bavi during this period (8 doses rather than 4).

Can anyone offer educated commentary on this point? From what we know so far about Bavi's MOA, are there not good grounds for expecting this new, 8-week treatment protocol to be much more effective than the 2-week treatment protocol?